Meropenem Venus (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used to treat serious bacterial infections in the hospital setting.

• Complicated intra‑abdominal infection: eradicates the causative pathogens, aiding rapid resolution of infection.
• Complicated urinary tract infection: provides effective bacterial clearance, reducing symptoms and preventing recurrence.
• Nosocomial pneumonia: targets resistant organisms, improving pulmonary outcomes.
• Bacterial meningitis: penetrates the cerebrospinal fluid to eliminate the infecting organisms.
• Severe Gram‑negative and Gram‑positive infections: offers broad coverage for life‑threatening sepsis.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its high affinity for a wide range of PBPs underlies its activity against many resistant Gram‑negative and Gram‑positive organisms.

Adverse reactions may occur with any antibiotic therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Injection site reaction: pain, erythema, or swelling at the infusion site.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile colitis: severe diarrhea due to overgrowth of C. difficile.
• Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin detachment.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Neutropenia: marked reduction in neutrophil count.

Use meropenem with careful clinical assessment and monitoring.

• Renal function: adjust dosing in patients with impaired renal clearance.
• Allergy: avoid in individuals with known hypersensitivity to carbapenems or beta‑lactams.
• Pregnancy: prescribe only when the potential benefit justifies the potential risk to the fetus.
• Valproic acid co‑administration: monitor for decreased valproate levels and possible seizure breakthrough.
• Concomitant nephrotoxic drugs: monitor renal parameters closely.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several medications, requiring clinical vigilance.

Major Interactions (Avoid)

• Valproic acid: carbapenems reduce plasma valproate concentrations, increasing seizure risk.
• CNS depressants: additive risk of seizures, especially in patients with pre‑existing CNS disorders.
• Nephrotoxic agents: concurrent use may exacerbate renal impairment.

Moderate Interactions (Monitor Closely)

• Loop diuretics: monitor electrolytes and renal function.
• Aminoglycosides: assess for additive nephrotoxicity.
• Warfarin: observe INR for potential anticoagulation changes.